Q2 2026 Precigen Inc Earnings Call Transcript
Key Points
- Precigen Inc (PGEN) reported exceptional Q2 2026 revenue of $53.1 million for Tapsimius, a 145% increase from Q1, and achieved quarterly net profitability before the first anniversary of FDA approval.
- The company has established a strong commercial foundation with payer coverage expanding to approximately 315 million covered lives, nearly all potential US covered lives, and the permanent J-code effective April 1 has facilitated routine use and account activation.
- Clinical durability data continues to strengthen, with 83% of patients in ongoing complete response beyond three years and some beyond four years surgery-free, reinforcing the drug's transformative efficacy.
- The FDA granted Tapsimius seven-year market exclusivity for adult RRP patients, protecting against prospective competition until August 2032.
- The company is advancing its pipeline, including PRGN-2009 for HPV-related cancers, with multiple Phase II trials and expected data updates later this year, highlighting the broader potential of the Adenoverse platform.
- The company's cash position is relatively low at $38.7 million, and it relies on the collection of $71.9 million in accounts receivable to fund operations through cash flow breakeven by end of 2026.
- Gross margins are expected to decline from the current 95% to the high 80s to low 90s percentage range after the sale of prelaunch inventory, indicating a potential reduction in profitability.
- The growth rate from Q1 to Q2 may not be sustainable, as management acknowledged that growth rates typically diminish over time after a launch.
- The company faces uncertainty in the trajectory of patient onboarding, with a significant proportion of treated patients coming from non-hub institutions, making it difficult to accurately track and forecast demand.
- R&D expenses are expected to increase as the year progresses, which could pressure future profitability despite the strong commercial performance.
Good afternoon, ladies and gentlemen, and welcome to the Precigen's second quarter 2026 financial results and business updates conference call. (Operator Instructions) This call is being recorded on Tuesday, August 4, 2026, and I would now like to turn the conference over to Harasim. Please go ahead.
Thank you, operator, and thank you to everyone joining us for Precigen's second-quarter 2026 update call. We are pleased to be speaking with you today as we continue to see strong momentum across the commercial launch of PEPs and MEOS. Joining me on today's call are Helen Sabzavari, our President and Chief Executive Officer Phil Tennant, our Chief Commercial Officer Harry Tomasian, our Chief Financial Officer. And Ritul Shah, our Chief Operating Officer. Helen will begin with an overview of the launch and key strategic updates.
Phil will provide additional details on the commercial execution. Harry will review our financial results and Ritul will be available for the Q&A section.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
